TPST

Tempest Therapeutics (TPST)

About Tempest Therapeutics (TPST)

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Details

Daily high

$2.28

Daily low

$1.80

Price at open

$2.24

52 Week High

$12.23

52 Week Low

$1.50

Market cap

32.1M

Dividend yield

0.00%

Volume

498,115

Avg. volume

381,357

P/E ratio

-.33

Tempest Therapeutics News